109 related articles for article (PubMed ID: 24856501)
1. Re: PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.
Wiwanitkit S
Int Braz J Urol; 2014; 40(2):285; author reply 286. PubMed ID: 24856501
[No Abstract] [Full Text] [Related]
2. PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.
Antunes AA; Reis ST; Leite KR; Real DM; Sousa-Canavez JM; Camara-Lopes LH; Dall'Oglio MF; Srougi M
Int Braz J Urol; 2013; 39(5):649-56. PubMed ID: 24267108
[TBL] [Abstract][Full Text] [Related]
3. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
[No Abstract] [Full Text] [Related]
4. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
[TBL] [Abstract][Full Text] [Related]
5. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
von Hardenberg J; Büsing KA; Nuhn P; Ritter M
Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
[TBL] [Abstract][Full Text] [Related]
6. PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Bao K; Lee JH; Kang H; Park GK; El Fakhri G; Choi HS
Chem Commun (Camb); 2017 Feb; 53(10):1611-1614. PubMed ID: 28085163
[TBL] [Abstract][Full Text] [Related]
7. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S; Wittmer C; Graefen M; Salomon G; Steuber T; Haese A; Huland H; Bokemeyer C; Yekebas E; Dierlamm J; Balabanov S; Kilic E; Wilczak W; Simon R; Sauter G; Schlomm T
Prostate; 2011 Feb; 71(3):281-8. PubMed ID: 20809553
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.
Schmidt B; Anastasiadis AG; Seifert HH; Franke KH; Oya M; Ackermann R
Anticancer Res; 2003; 23(5A):3991-9. PubMed ID: 14666708
[TBL] [Abstract][Full Text] [Related]
9. Imaging of Prostate-Specific Membrane Antigen Using [
Rowe SP; Gorin MA; Pomper MG
PET Clin; 2017 Jul; 12(3):289-296. PubMed ID: 28576167
[TBL] [Abstract][Full Text] [Related]
10. Expression of prostate-specific membrane antigen in normal and malignant human tissues.
Kinoshita Y; Kuratsukuri K; Landas S; Imaida K; Rovito PM; Wang CY; Haas GP
World J Surg; 2006 Apr; 30(4):628-36. PubMed ID: 16555021
[TBL] [Abstract][Full Text] [Related]
11. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
13. Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Barwe SP; Maul RS; Christiansen JJ; Anilkumar G; Cooper CR; Kohn DB; Rajasekaran AK
Int J Oncol; 2007 Apr; 30(4):899-904. PubMed ID: 17332929
[TBL] [Abstract][Full Text] [Related]
14. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
[TBL] [Abstract][Full Text] [Related]
15. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
Wu LY; Liu T; Grimm AL; Davis WC; Berkman CE
Prostate; 2011 Jan; 71(1):52-61. PubMed ID: 20632319
[TBL] [Abstract][Full Text] [Related]
17. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
18. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
O'Keefe DS; Bacich DJ; Heston WD
Prostate; 2004 Feb; 58(2):200-10. PubMed ID: 14716746
[TBL] [Abstract][Full Text] [Related]
20. Anti-PSMA antibody-coupled gold nanorods detection by optical and electron microscopies.
Schol D; Fleron M; Greisch JF; Jaeger M; Frenz M; De Pauw E; De Pauw-Gillet MC
Micron; 2013 Jul; 50():68-74. PubMed ID: 23777855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
